Trials / Terminated
TerminatedNCT03786380
Diabetic Gastroparesis Study 05
Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 \[NCT03420781\] or RLM-MD-04 \[NCT03383146\] study and to provide treatment for these participants until relamorelin becomes commercially available or the Sponsor terminates development.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Relamorelin 10 μg | Relamorelin 10 μg injected subcutaneously twice daily. |
Timeline
- Start date
- 2018-12-20
- Primary completion
- 2020-10-05
- Completion
- 2020-10-05
- First posted
- 2018-12-26
- Last updated
- 2021-12-15
- Results posted
- 2021-12-15
Locations
486 sites across 30 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Denmark, France, Germany, Hungary, India, Israel, Italy, Latvia, Malaysia, Mexico, Philippines, Poland, Romania, Russia, Singapore, South Africa, South Korea, Spain, Thailand, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03786380. Inclusion in this directory is not an endorsement.